Table 2 Comparison of baseline characteristics between the “not present” and “at least mild” groups
Not present (n = 124) number (%) | Mild or above (n = 212) number (%) | p value | |
|---|---|---|---|
Male/female | 74 (59.7)/50 (40.3) | 139 (65.6)/73 (34.4) | 0.280* |
Median, IQR age (years) | 69, 62–76 | 71, 63–78 | 0.275** |
Median, IQR duration of hemodialysis (months) | 72, 30–152 | 63, 34–123 | 0.301** |
Primary illness of chronic kidney disease | |||
Diabetes mellitus | 50 (40.3) | 102 (48.1) | 0.166* |
Chronic glomerulonephritis | 38 (30.6) | 49 (23.1) | 0.128* |
Nephrosclerosis | 12 (9.7) | 23 (10.8) | 0.734* |
Other | 15 (12.1) | 20 (9.4) | 0.441* |
Unknown | 9 (7.3) | 18 (8.5) | 0.688* |
Comorbidities | |||
Hypertension | 114 (91.9) | 198 (93.4) | 0.616* |
Ischemic heart disease | 24 (19.4) | 55 (25.9) | 0.169* |
Congestive heart failure | 27 (21.8) | 37 (17.5) | 0.330* |
Cerebral vascular disease | 28 (22.6) | 57 (26.9) | 0.381* |
Peripheral arterial disease | 15 (12.1) | 24 (11.3) | 0.830* |
Chronic lung disease | 8 (6.5) | 16 (7.5) | 0.707* |
Chronic liver disease | 3 (2.4) | 16 (7.5) | < 0.05* |
Malignant neoplasm | 6 (4.8) | 13 (6.1) | 0.620* |
Medication for pruritus | |||
Moisturizers | 27 (21.8) | 115 (54.2) | < 0.001* |
Topical steroids | 5 (4.0) | 78 (36.8) | < 0.001* |
Other topical drugs | 3 (2.4) | 32 (15.1) | < 0.001* |
Oral antihistamines | 2 (1.6) | 11 (5.2) | 0.143*** |
Anti-allergy injections | 0 (0.0) | 2 (0.9) | 0.533*** |
Nalfurafine | 10 (8.1) | 29 (13.7) | 0.121* |
Laboratory parameters (median, IQR) | |||
Serum albumin (g/dL) | 3.7, 3.5–3.8 | 3.6, 3.4–3.8 | 0.164** |
Serum corrected calcium (mg/dL) | 8.8, 8.5–9.2 | 8.8, 8.4–9.2 | 0.949** |
Phosphorus (mg/dL) | 4.9, 4.2–5.4 | 4.8, 3.9–5.5 | 0.937**** |
Whole PTH (pg/mL) | 63.6, 47.4–101.4 | 81.8, 55.0–124.9 | < 0.05** |
Hemoglobin (g/dL) | 11.4, 10.7–12.0 | 11.3, 10.8–11.9 | 0.557** |
β2-microglobulin (mg/L) | 22.9, 19.9–25.9 | 23.0, 20.1–26.5 | 0.571** |
Kt/V | 1.5, 1.4–1.6 | 1.5, 1.4–1.6 | 0.760***** |